Immix Biopharma (NASDAQ:IMMX) Announces Earnings Results, Misses Expectations By $0.01 EPS

Posted by George Bondi on Aug 7th, 2026

Immix Biopharma (NASDAQ:IMMX – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01), Zacks reports.

Immix Biopharma Trading Down 3.4%

NASDAQ:IMMX traded down $0.34 during trading hours on Friday, hitting $9.72. The stock had a trading volume of 1,604,682 shares, compared to its average volume of 1,654,168. The company has a market cap of $528.87 million, a PE ratio of -10.57 and a beta of 0.11. The business has a 50 day simple moving average of $9.38 and a two-hundred day simple moving average of $8.82. Immix Biopharma has a 1-year low of $1.94 and a 1-year high of $12.14.

Wall Street Analysts Forecast Growth

IMMX has been the subject of several research reports. Bank of America started coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 price objective for the company. Needham & Company LLC began coverage on shares of Immix Biopharma in a report on Wednesday, July 22nd. They set a “buy” rating and a $21.00 target price on the stock. HC Wainwright upped their price target on shares of Immix Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th. Finally, Lifesci Capital assumed coverage on Immix Biopharma in a research report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Immix Biopharma presently has an average rating of “Moderate Buy” and an average price target of $20.71.

Read Our Latest Analysis on Immix Biopharma

Institutional Investors Weigh In On Immix Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new position in Immix Biopharma in the 4th quarter valued at about $20,471,000. Marshall Wace LLP increased its position in shares of Immix Biopharma by 3,495.4% during the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after acquiring an additional 1,923,708 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Immix Biopharma during the fourth quarter worth about $8,681,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Immix Biopharma in the fourth quarter worth about $7,845,000. Finally, Logos Global Management LP acquired a new position in shares of Immix Biopharma in the fourth quarter worth about $5,230,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.